|
1
|
Deng Y, Chan SS and Chang S: Telomere
dysfunction and tumour suppression: The senescence connection. Nat
Rev Cancer. 8:450–458. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palm W and de Lange T: How shelterin
protects mammalian telomeres. Annu Rev Genet. 42:301–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart SA and Weinberg RA: Telomeres:
Cancer to human aging. Annu Rev Cell Dev Biol. 22:531–557. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harley CB, Futcher AB and Greider CW:
Telomeres shorten during ageing of human fibroblasts. Nature.
345:458–460. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Zglinicki T: Oxidative stress shortens
telomeres. Trends Biochem Sci. 27:339–344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harley CB and Villeponteau B: Telomeres
and telomerase in aging and cancer. Curr Opin Genet Dev. 5:249–255.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Lange T: Telomeres and senescence:
Ending the debate. Science. 279:334–335. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
DePinho RA: The age of cancer. Nature.
408:248–254. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Artandi SE and DePinho RA: Telomeres and
telomerase in cancer. Carcinogenesis. 31:9–18. 2010. View Article : Google Scholar :
|
|
10
|
Blasco MA: Telomeres and human disease:
Ageing, cancer and beyond. Nat Rev Genet. 6:611–622. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prescott J, Wentzensen IM, Savage SA and
De Vivo I: Epidemiologic evidence for a role of telomere
dysfunction in cancer etiology. Mutat Res. 730:75–84. 2012.
View Article : Google Scholar
|
|
12
|
Svenson U and Roos G: Telomere length as a
biological marker in malignancy. Biochim Biophys Acta.
1792:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kurabayashi R, Takubo K, Aida J, Honma N,
Poon SS, Kammori M, Izumiyama-Shimomura N, Nakamura K, Tsuji E,
Matsuura M, et al: Luminal and cancer cells in the breast show more
rapid telomere shortening than myoepithelial cells and fibroblasts.
Hum Pathol. 39:1647–1655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meeker AK, Hicks JL, Iacobuzio-Donahue CA,
Montgomery EA, Westra WH, Chan TY, Ronnett BM and De Marzo AM:
Telomere length abnormalities occur early in the initiation of
epithelial carcinogenesis. Clin Cancer Res. 10:3317–3326. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meeker AK and Argani P: Telomere
shortening occurs early during breast tumorigenesis: A cause of
chromosome destabilization underlying malignant transformation? J
Mammary Gland Biol Neoplasia. 9:285–296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meeker AK, Hicks JL, Gabrielson E, Strauss
WM, De Marzo AM and Argani P: Telomere shortening occurs in subsets
of normal breast epithelium as well as in situ and invasive
carcinoma. Am J Pathol. 164:925–935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chin K, de Solorzano CO, Knowles D, Jones
A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K, et al:
In situ analyses of genome instability in breast cancer. Nat Genet.
36:984–988. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Odagiri E, Kanada N, Jibiki K, Demura R,
Aikawa E and Demura H: Reduction of telomeric length and c-erbB-2
gene amplification in human breast cancer, fibroadenoma, and
gynecomastia. Relationship to histologic grade and clinical
parameters. Cancer. 73:2978–2984. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Griffith JK, Bryant JE, Fordyce CA,
Gilliland FD, Joste NE and Moyzis RK: Reduced telomere DNA content
is correlated with genomic instability and metastasis in invasive
human breast carcinoma. Breast Cancer Res Treat. 54:59–64. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Radpour R, Barekati Z, Haghighi MM, Kohler
C, Asadollahi R, Torbati PM, Holzgreve W and Zhong XY: Correlation
of telomere length shortening with promoter methylation profile of
p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol.
23:763–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fordyce CA, Heaphy CM, Bisoffi M, Wyaco
JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC
and Griffith JK: Telomere content correlates with stage and
prognosis in breast cancer. Breast Cancer Res Treat. 99:193–202.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rogalla P, Rohen C, Bonk U and Bullerdiek
J: Telomeric repeat fragment lengths are not correlated to
histological grading in 85 breast cancers. Cancer Lett.
106:155–161. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sugishita Y, Kammori M, Yamada O, Yamazaki
K, Ito K, Fukumori T, Yoshikawa K and Yamada T: Biological
differential diagnosis of follicular thyroid tumor and Hürthle cell
tumor on the basis of telomere length and hTERT expression. Ann
Surg Oncol. 21:2318–2325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aida J, Izumiyama-Shimomura N, Nakamura K,
Ishii A, Ishikawa N, Honma N, Kurabayashi R, Kammori M, Poon SS,
Arai T, et al: Telomere length variations in 6 mucosal cell types
of gastric tissue observed using a novel quantitative fluorescence
in situ hybridization method. Hum Pathol. 38:1192–1200. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kammori M, Izumiyama N, Nakamura K,
Kurabayashi R, Kashio M, Aida J, Poon SS and Kaminishi M: Telomere
metabolism and diagnostic demonstration of telomere measurement in
the human esophagus for distinguishing benign from malignant tissue
by tissue quantitative fluorescence in situ hybridization.
Oncology. 71:430–436. 2006. View Article : Google Scholar
|
|
27
|
Ahlin C, Aaltonen K, Amini RM, Nevanlinna
H, Fjällskog ML and Blomqvist C: Ki67 and cyclin A as prognostic
factors in early breast cancer. What are the optimal cut-off
values? Histopathology. 51:491–498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knutsvik G, Stefansson IM, Aziz S, Arnes
J, Eide J, Collett K and Akslen LA: Evaluation of Ki67 expression
across distinct categories of breast cancer specimens: A
population-based study of matched surgical specimens, core needle
biopsies and tissue microarrays. PLoS One. 9:e1121212014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Donaldson L, Fordyce C, Gilliland F, Smith
A, Feddersen R, Joste N, Moyzis R and Griffith J: Association
between outcome and telomere DNA content in prostate cancer. J
Urol. 162:1788–1792. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frías C, García-Aranda C, De Juan C, Morán
A, Ortega P, Gómez A, Hernando F, López-Asenjo JA, Torres AJ,
Benito M, et al: Telomere shortening is associated with poor
prognosis and telomerase activity correlates with DNA repair
impairment in non-small cell lung cancer. Lung Cancer. 60:416–425.
2008. View Article : Google Scholar
|
|
33
|
Bisoffi M, Heaphy CM and Griffith JK:
Telomeres: Prognostic markers for solid tumors. Int J Cancer.
119:2255–2260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heaphy CM, Baumgartner KB, Bisoffi M,
Baumgartner RN and Griffith JK: Telomere DNA content predicts
breast cancer-free survival interval. Clin Cancer Res.
13:7037–7043. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Diehl MC, Idowu MO, Kimmelshue KN, York
TP, Jackson-Cook CK, Turner KC, Holt SE and Elmore LW: Elevated
TRF2 in advanced breast cancers with short telomeres. Breast Cancer
Res Treat. 127:623–630. 2011. View Article : Google Scholar
|
|
36
|
Carter CL, Allen C and Henson DE: Relation
of tumor size, lymph node status, and survival in 24,740 breast
cancer cases. Cancer. 63:181–187. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leitner SP, Swern AS, Weinberger D, Duncan
LJ and Hutter RV: Predictors of recurrence for patients with small
(one centimeter or less) localized breast cancer (T1a,b N0 M0).
Cancer. 76:2266–2274. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gebauer G, Fehm T, Lang N and Jäger W:
Tumor size, axillary lymph node status and steroid receptor
expression in breast cancer: Prognostic relevance 5 years after
surgery. Breast Cancer Res Treat. 75:167–173. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Voduc KD, Cheang MC, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Heaphy CM, Subhawong AP, Gross AL, Konishi
Y, Kouprina N, Argani P, Visvanathan K and Meeker AK: Shorter
telomeres in luminal B, HER-2 and triple-negative breast cancer
subtypes. Mod Pathol. 24:194–200. 2011. View Article : Google Scholar
|
|
45
|
Martinez-Delgado B, Gallardo M, Tanic M,
Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M,
Cañamero M, Blasco MA and Benitez J: Short telomeres are frequent
in hereditary breast tumors and are associated with high tumor
grade. Breast Cancer Res Treat. 141:231–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
